|
|
Blood, 1 July 2007, Vol. 110, No. 1, pp. 305-312.
Prepublished online as a Blood First Edition Paper on March 20, 2007; DOI 10.1182/blood-2006-07-033209.
 Previous Article | Next Article 
Submitted July 5, 2006
Accepted March 9, 2007
Ubp43 regulates BCR-ABL leukemogenesis via
the Type I interferon receptor signaling
Ming Yan, Jiann-Kae Luo, Kenneth J. Ritchie, Ikuya Sakai, Kasuto Takeuchi, Ruibao Ren, and Dong-Er Zhang*
Division of Oncovirology, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, United States
First Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan
Department of Biology, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, MA, United States
* Corresponding author; email: dzhang{at}scripps.edu.
Interferon (IFN) signaling induces the expression of interferon responsive genes and leads to the activation of pathways that are involved in the innate immune response. Ubp43 is an ISG15 specific isopeptidase, the expression of which is activated by IFN. Ubp43 knockout mice are hypersensitive to IFN- / and have enhanced resistance to lethal viral and bacterial infections. Here we show that in addition to protection against foreign pathogens, Ubp43 deficiency increases the resistance to oncogenic transformation by BCR-ABL. BCR-ABL viral transduction/transplantation of wild-type bone marrow cells results in the rapid development of a chronic myeloid leukemia (CML)-like myeloproliferative disease, in contrast a significantly increased latency of disease development is observed following BCR-ABL viral transduction/transplantation of Ubp43 deficient bone marrow cells. This resistance to leukemic development is dependent on Type I IFN (IFN-/) signaling in Ubp43 deficient cells. Increased levels of Type I IFN are also detected in the serum of CML mice. These results suggest that inhibition of Ubp43 negative effect on IFN signaling can potentiate the response to increased endogenous IFN levels in innate immune responses against cancer development, indicating that pharmacological inhibition of Ubp43 may be of benefit in cancers and others diseases in which interferon is currently prescribed.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Potu, A. Sgorbissa, and C. Brancolini
Identification of USP18 as an Important Regulator of the Susceptibility to IFN-{alpha} and Drug-Induced Apoptosis
Cancer Res.,
January 15, 2010;
70(2):
655 - 665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Feng, D. Sekula, Y. Guo, X. Liu, C. C. Black, F. Galimberti, S. J. Shah, L. F. Sempere, V. Memoli, J. B. Andersen, et al.
UBE1L causes lung cancer growth suppression by targeting cyclin D1
Mol. Cancer Ther.,
December 1, 2008;
7(12):
3780 - 3788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-H. Kim, J.-K. Luo, and D.-E. Zhang
The Level of Hepatitis B Virus Replication Is Not Affected by Protein ISG15 Modification but Is Reduced by Inhibition of UBP43 (USP18) Expression
J. Immunol.,
November 1, 2008;
181(9):
6467 - 6472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Katsoulidis, A. Sassano, B. Majchrzak-Kita, N. Carayol, P. Yoon, A. Jordan, B. J. Druker, E. N. Fish, and L. C. Platanias
Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells
J. Biol. Chem.,
April 18, 2008;
283(16):
10793 - 10803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
